Oct 252014
 

 

 

The continuous flow synthesis of carboxylic acids using CO2 in a tube-in-tube gas permeable membrane reactor

A. Polyzos, M. O’Brien, T. Pugaard-Petersen, I.R. Baxendale, S.V. Ley, Angew. Chem. Int. Ed. 2011, 50, 1190-1193.

http://onlinelibrary.wiley.com/doi/10.1002/anie.201006618/abstract

http://onlinelibrary.wiley.com/store/10.1002/anie.201006618/asset/supinfo/anie_201006618_sm_miscellaneous_information.pdf?v=1&s=eeb1de81511ff2fac7a88009df9f45da49384532

Keep it simple: A gas–liquid flow reactor has been developed based on a gas permeable tube-in-tube configuration which effectively delivers gas to a liquid substrate stream in a safe, continuous fashion. A series of carboxylic acids were prepared from the reaction of CO2with a range of Grignard reagents (see picture).

The gas-liquid reactor assembly is comprised of a 1 m section of Teflon AF-
2400 tubing (0.8 mm o.d.; 0.6 mm i.d.) placed within PTFE tubing (3.2 mm o.d.; 1.6
mm i.d). These tubings were coiled and each end fastened to a 1/8” stainless steel tube
fitting, which was fixed onto an aluminium base plate. One section of the Teflon AF-
2400 membrane tubing was passed through to a stainless steel T-piece (Swagelok 2 ×
1/8”, 1 × 16” fittings) that was united with PTFE tubing (1/16”), forming the liquid
inlet. The other section of the Teflon AF-2400 was passed through a 4-way stainless
steel connector (Swagelok, 3 × 1/8”, 1 × 16” fittings) and directly united with a
second piece of PTFE tubing (1/16”), forming the liquid outlet. One of the 1/8”
fittings on the 4-way connector was attached to a fine needle release valve (Swagelok)
used to purge the reactor of excess gas. The remaining connector was attached to
another stainless steel T-piece (Swagelok 3 × 1/8” fittings) that was connected to a
pressure gauge (Swagelok, 10 Bar) and a gas pressure regulator valve (10 bar
maximum) via stainless steel tubing (1/8”) (Figure S1).

Inline image 1

Inline image 2

 

Two flow streams driven by the Vapourtec R4/R2+; stream 1 containing a
solution of 1a (1.0 M in THF, 1.0 equiv, 1.0 mmol) loaded into a 2mL PEEK loop
and stream 2 containing the dry THF, were mixed at a T-piece before entering the
gas-liquid tube-in-tube reactor at room temperature. A back pressure regulator (75
psi) was placed immediately after the gas-liquid reactor to prevent out-gassing of the
dissolved CO2 from the solvent stream in the reactor. The flow stream was collected
in a flask containing a biphasic mixture of saturated ammonium chloride solution and
diethyl ether (1:1) (20 mL). The solution was acidified with HCl (1.0 M) and the
product was extracted with EtOAc (2 × 10 mL), dried (Na2SO4) and solvent removed
in vacuo to give the crude product 1b.

 

Share
Oct 182014
 

MOM

DIISOPROPYLAMINE

C6H15N

MW 101

the degree of unsaturation: the answer is 0. The molecule has no double bonds or rings.

 

 

IR Spectrum

Since the molecule has a nitrogen, look for a band in the region 3400-3250 – there is a single small band at 3384, which probably indicates the N-H stretch of a secondary amine. (Recall that tertiary amines will not show a band in this region because they do not have any N-H’s to stretch.)

 

 

 

NMR Spectrum

 

Diisopropylamine(108-18-9)1HNMR

 

 

Amine protons show up from 0.5-3.0 ppm if the amine is not on an aromatic ring; the small “buried” peak at 1 ppm indicates a secondary amine peak:

There are only two other types of protons in the molecule: the doublet at 1 ppm indicates 12 hydrogens adjacent to one hydrogen and the septet at 2.9 ppm indicates 2 hydrogens adjacent to 6 hydrogens. The only way the molecule can be “put together” is to have each R group coming off the nitrogen to be the same, and to be -CH(CH3)2.

13C NMR

MASS

 

Summary

Example is diisopropylamine:

Share
Oct 172014
 
Chemical structure of prismane
PRISMANE

650-42-0 cas

Tetracyclo[2.2.0.02,6.03,5]hexane

Prismane is a polycyclic hydrocarbon with the formula C6H6. It is an isomer of benzene, specifically a valence isomer. Prismane is far less stable than benzene. The carbon (and hydrogen) atoms of the prismane molecule are arranged in the shape of a six-atomtriangular prismAlbert Ladenburg proposed this structure for the compound now known as benzene.[1] The compound was not synthesized until 1973.[2]
Prismane
Chemical structure of prismane Chemical structure of prismane
CPK model of prismane
Identifiers
CAS number 650-42-0 
ChemSpider 16736515 Yes
Jmol-3D images Image 1
Properties
Molecular formula C6H6
Molar mass 78.11 g mol−1

History

In the mid 19th century, investigators proposed several possible structures for benzene which were consistent with its empirical formula, C6H6, which had been determined by combustion analysis. The first, which was proposed by Kekulé in 1867, later proved to be closest to the true structure of benzene. This structure inspired several others to propose structures that were consistent with benzene’s empirical formula; for example, Ladenburg proposed prismane, Dewar proposed Dewar benzene, and Koerner and Claus proposedClaus’ benzene. Some of these structures would be synthesized in the following years. Prismane, like the other proposed structures for benzene, is still often cited in the literature, because it is part of the historical struggle toward understanding the mesomeric structures and resonance of benzene. Some computational chemists still research the differences between the possible isomers of C6H6.[3]

Properties

Prismane is a colourless liquid at room temperature. The deviation of the carbon-carbon bond angle from 109° to 60° in a triangle leads to a high ring strain, reminiscent of that of cyclopropane but greater. The compound is explosive, which is unusual for a hydrocarbon. Due to this ring strain, the bonds have a low bond energy and break at a low activation energy, which makes synthesis of the molecule difficult; Woodward and Hoffmann noted that prismane’s thermal rearrangement to benzene is symmetry-forbidden, comparing it to “an angry tiger unable to break out of a paper cage.”[4]

The substituted derivative hexamethylprismane (in which all six hydrogens are substituted by methyl groups) has a higher stability, and was synthesized by rearrangement reactionsin 1966.[5]

Synthesis

Synthesis of Prismane

The synthesis starts from benzvalene (1) and 4-phenyltriazolidone, which is a strong dienophile. The reaction is a stepwise Diels-Alder like reaction, forming a carbocation as intermediate. The adduct (2) is then hydrolyzed under basic conditions and afterwards transformed into a copper(II) chloride derivative with acidic copper(II) chloride. Neutralized with a strong base, the azo compound (3) could be crystallized with 65% yield. The last step is a photolysis of the azo compound. This photolysis leads to a biradical which forms prismane (4) and nitrogen with a yield of less than 10%. The compound was isolated by preparative gas chromatography.

 

SYNTHESIS
Chemical structure
MeLi, CH2Cl2, 
Et2O
-45 °C, 45 %
Chemical structure

+

Chemical structure

Et2O, Dioxane
0 °C to RT, 60 min, 50-60 %

Chemical structure
KOH, 
MeOH, H2O
Reflux, 24 h
Chemical structure
CuCl2, HCl,
H2O
65 % (2 steps)
Chemical structure
hν, 
PhMe
30 °C, 5 h, 8 %
Chemical structure
References

 

 

https://www.beilstein-journals.org/bjoc/single/printArticle.htm?publicId=1860-5397-7-30

 

 

http://chemistry.stackexchange.com/questions/8898/does-benzene-have-isomers-and-resonance-structures

References

  1. Ladenburg A. (1869). “Bemerkungen zur aromatischen Theorie“. Chemische Berichte 2: 140–2. doi:10.1002/cber.18690020171.
  2. Katz T. J., Acton N. (1973). “Synthesis of Prismane”. Journal of the American Chemical Society 95 (8): 2738–2739. doi:10.1021/ja00789a084.
  3.  UD Priyakumar, TC Dinadayalane, GN Sastry (2002). “A computational study of the valence isomers of benzene and their group V hetero analogs”New J. Chem. 26 (3): 347–353.doi:10.1039/b109067d.
  4. R. B. Woodward and R. Hoffmann, Angew. Chem., Int. Ed. Engl.8, 789, (1969)
  5.  Lemal D. M., Lokensgard J. P. (1966). “Hexamethylprismane”. Journal of the American Chemical Society 88 (24): pp 5934–5935. doi:10.1021/ja00976a046.
Share
Oct 092014
 

ALL ABOUT DRUGS
 

Highly potent APIs: can lean manufacturing ever be safe?

By Fiona Barry +, 09-Oct-2014

The phrase “lean manufacturing” conjures up job cuts and not much more for many people, but managers can use the method to drastically simplify HPAPI (highly potent active pharmaceutical ingredients) production, says an expert.

http://www.in-pharmatechnologist.com/Processing/Highly-potent-APIs-can-lean-manufacturing-ever-be-safe

Share
Oct 092014
 

 

 

Green chemistry makes ‘cents’ for cost-focused API firms says expert

By Gareth MacDonald+, 07-Oct-2014

Making drugs generates a huge amount of waste but industry is showing signs of cleaning up its act according to Paul Anastas, the Yale scientist who coined the phrase “green chemistry.”

http://www.in-pharmatechnologist.com/Ingredients/Green-chemistry-makes-cents-for-cost-focused-API-firms-says-expert

Share
Oct 082014
 
Dr. Rafael "Rafi" Boritzer

DR RAFAEL BORITZER

Global Biotech Marketer, Serial Entrepreneur, Academician, Chair of Bioinfomedical Ltd. (www.bioinfomedical.com)
WE SALUTE YOU, SIR ……for your enormous contribution to society

WE SALUTE YOU SIR

His public appeal in his own words
Aloha Bio Research-Education Friends and Colleagues,I appreciate your recent linking to me on the LinkedIn network and directly at boritzer@bioinfomedical.com Our Mission is to provide molecular biological product support, for research and development of Biosimilars, Personalized Medicine, and Traditional Pharma.Through our networks and relationships in over 60 countries, we help engage the scientific community in the cure and treatment of life-threatening and newly emerging diseases. You can find us at www.bioinfomedical.com , where our enterprise guarantees the highest levels of purity at “budget-constrained” prices. If you prefer to “buy the machine” instead of the product, we do offer the technology to produce any of our over 3,500 recombinant proteins and antibodies. If you do not find what you need in our online catalog (bottom right of landing page), we will be happy to entertain custom orders.With our accumulated experience in graduate and distance learning, we actively encourage, participate, and support American biotechnology and biological sciences education (Certificate, Masters, and Ph.D.). Our hybrid formats integrate short campus residency at first rate “bricks and mortar” campuses, on-line synchronous and asynchronous instruction, and the use of strategically located research labs in the U.S.A., Europe, and Asia.We look forward to meeting your needs.Thank you,
Dr. Rafi

Dr. Rafael "Rafi" Boritzer

Dr. Rafael “Rafi” Boritzer

Global Biotech Marketer, Serial Entrepreneur, Academician, Chair of Bioinfomedical Ltd.

CURRENT
  1. ThinkTech Hawaii,
  2. Bioinfomedical Ltd. / InfoMedical L.L.C.http://www.linkedin.com/in/doctorboritzer

 

Chairman of the Board of Directors

Bioinfomedical Ltd. / InfoMedical L.L.C. 

Started and built entrepreneurial venture that began as a consulting firm and grew into a successful business engaged in the global transfer of medical/gerontological technologies and software, marketing of research cytokines, and strategic alliances with bio-similar producers. Fostered relationships in Hawaii, Central/Southeast Asia, Oceania, Central Europe, Middle East, and East Africa, to accelerate growth of the business and further its objectives. Created differentiation strategies designed to cope with competitive marketing pressures primarily in long-term healthcare, specialty medical institutions and pharmaceutical distributors in the U.S. and Southeast Asia.

 

Dr. Rafi on Sociology at the University of Hawaii

Dr. Rafi on Sociology at the University of Hawaii

 

 

ABOUT HIM BY HIM

Over the course of my 20+ year career as an interdisciplinary and multicultural university educator, social scientist, marketer, entrepreneur and administrator, I have directed organizations, programs and initiatives that promote academic excellence, improve student performance, and strengthen educational outcomes. I have taught at Professor levels in the disciplines of healthcare administration, healthcare management information systems, sociology, global marketing and more. I have a track record in leading and participating in accreditation requirements, and in driving the design and development of curriculum and course offerings, at both graduate and undergraduate levels. My international experience encompasses five continents and I have an in-depth understanding of geopolitical contexts of business and effects on global and local economy and education.

Complementing my teaching and administrative background is executive and research experience in healthcare, geriatrics, entrepreneurship, and marketing, including the conceptualization, startup, and growth of a successful firm engaged in the global transfer of medical/gerontological technologies and software, marketing of research cytokines, and strategic alliances. InfoMedical Biotechnology (www.bioinfomedical.com) satisfies customers’ demand for high quality cytokine products. The use of medical diagnostics is growing in importance, as bigger proportion of the world’s population age and the cost of healthcare continues to rise. The company provides scientists with tools to investigate the genetic and molecular basis for human development and disease; knowledge that is applied in development, discovery and manufacture of new drugs.

Specialties: Education Program Development; Teaching; Student Recruitment-Retention; Distance Learning Modalities; Research & funding; Community Health; Sustainable Entrepreneurship; Strategic Planning; Sociology; Disruptive Innovation; and Global Business Strategies.

Senior project presentations at University of Hawaii Entrepreneurship Baccalaureate

Senior project presentations at University of Hawaii Entrepreneurship Baccalaureate

Live Life Aloha Obesity Reduction

Live Life Aloha Obesity Reduction

 

More about him

TV Talk Show Host

ThinkTech Hawaii

 – Present (10 months)Honolulu, HawaiiDr. Rafi conducts the weekly broadcast of Boritzer’s Bio Briefings. The hourly show focuses on the Biotechnological, Health and Medical sectors that are changing the way we live, eat, work, and socialize in the 21st Century. www.thinktechhawaii.com (live streaming on Mondays @ 15:00 Hawaiian Standard Time). Available after 24 hours (http://tinyurl.com/lnulduz).

From New York to Singapore, "Hospitals I've Learned to Love" with Dr. Rafi Boritzer

From New York to Singapore, “Hospitals I’ve Learned to Love” with Dr. Rafi Boritzer

Dr. Rafi Reveals IUI, IVF & Transactions at the Sperm Bank

Dr. Rafi Reveals IUI, IVF & Transactions at the Sperm Bank

Live, Life with Aloha - Obesity Reduction MadeEasy- Dr. Rafi Boritzer

Live, Life with Aloha – Obesity Reduction MadeEasy- Dr. Rafi Boritzer

The Health Care Highway -From Kolkata to Kapolei with Dr. Rafael Boritzer

The Health Care Highway -From Kolkata to Kapolei with Dr. Rafael Boritzer

Tele Medicine Systems - Dr. Rafi Boritzer with Dr. Dan Davis

Tele Medicine Systems – Dr. Rafi Boritzer with Dr. Dan Davis

In Telomere Research, SIZE is Everything-Dr. Rafi and Prof. Richard Allsopp

In Telomere Research, SIZE is Everything-Dr. Rafi and Prof. Richard Allsopp

If You Are A Baby Boomer, The Future is Now

If You Are A Baby Boomer, The Future is Now

Dr. Rafi chats with Prof. Tom Huang, Lab Director @ Pacific InVitro Fertilization

Dr. Rafi chats with Prof. Tom Huang, Lab Director @ Pacific InVitro Fertilization

Dr. Rafi and Prof. Clair Wright discuss "Pregnancy Dangers and Outcomes"

Dr. Rafi and Prof. Clair Wright discuss “Pregnancy Dangers and Outcomes”

Islands of Health- Dr Rafi on Fiji, Timor-Leste, Singapore, Madagascar, and Sicily

Islands of Health- Dr Rafi on Fiji, Timor-Leste, Singapore, Madagascar, and Sicily

Dr. Rafi Chases Ambulances from Honolulu to Tahrir Square

Dr. Rafi Chases Ambulances from Honolulu to Tahrir Square

Who is following you when you check into a long term care facility - Boritzer's Bio Briefings

Who is following you when you check into a long term care facility – Boritzer’s Bio Briefings

Cuban Healthcare: Can you achieve more with less?

Cuban Healthcare: Can you achieve more with less?

VITEC POSTER

 

 

Canoe Blessing 1 of 2

Canoe Blessing 1 of 2

Canoe Blessing 2 of 2

Canoe Blessing 2 of 2

Dr. Rafi on Globalization at University of Hawaii

Dr. Rafi on Globalization at University of Hawaii

Dr. Rafi on Entrepreneurship at the University of Hawaii

Dr. Rafi on Entrepreneurship at the University of Hawaii

  1. Advice for Contacting Dr. Rafael “Rafi”

    As as an academic and consultant, I am available for year round consulting projects and visiting professor assignments. Contact: boritzer@bioinfomedical.com , LinkedIn messages, Facebook messages.

This was my tribute to a great living legend

Share
Oct 062014
 
09240-notw8-pcr_18276322-690

SETTING PRIORITIES
A real-time PCR technique saves time and energy in natural product drug discovery by screening microbes for those that biosynthesize desired compound families.
Credit: J. Nat. Prod.

Direct Route To Natural Products

Drug Discovery: Technique zeroes in on microbes that biosynthesize specific compound families
read all at
Share
Oct 022014
 

 

Lanoconazole

READ AT http://newdrugapprovals.org/2014/10/02/lanoconazole/

  • Latoconazole, Lanoconazole, TJN-318, NND-318, Astat,

Nihon Nohyaku (Originator), Tsumura (Licensee)

Synonym: 2-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrile
Application: An antifungal compound
CAS Number: 101530-10-3
Molecular Weight: 319.83
Molecular Formula: C14H10ClN3S2

Brief background information

Technical Information
Appearance: Crystalline
Physical State: Solid
Solubility: Soluble in chloroform, and methanol. Insoluble in water.
Storage: Store at -20° C
Melting Point: 129-132 °C
Boiling Point: ~477.6 °C at 760 mmHg (Predicted)
Density: ~1.4 g/cm3 (Predicted)
Refractive Index: n20D 1.73 (Predicted)
pK Values: pKb: 3.76 (Predicted)
Safety and Reference Information
WGK Germany: 3
RTECS: NI3393500
PubChem CID: 3002820
Merck Index: 14: 5357
MDL Number: MFCD00865590
Beilstein Registry: 4819111
Salt ATC Formula MM CAS
- D01 14 H 10 ClN 3 S 2 319.84 g / mol 101530-10-3

Lanoconazole

Application

  • antifungal

Synthesis pathway

Synthesis a)

 

Synthetic route
The reaction of 2- (1-imidazolyl) acetonitrile (I) with CS2 and KOH in DMF gives the dithiolate (II), which is then cyclized with 1- (2-chlorophenyl) -1,2-di (methanesulfonyloxy) ethane . (III) A column chromatography over silicagel allows the separation of the (E) -.? and (Z) -isomers (1-5)
Description Crystals, mp 141-5 Manufacturer Nihon Nohyaku Co., Ltd. (Japan) and Tsumura Juntendo (Japan).
References 1. Seo, A., Kanno, H., Hasegawa, N. et al. (Nihon Nohyaku Co., Ltd.). Antimycotic agent and fungicidal agent. US 4738976. 2. Seo, A ., Sugano, H., Hasegawa, C., Ikeda, K., Munechica, Y., Konoe, T., Konaka, M. (Nihon Nohyaku Co., Ltd.). Antifungal agent. JP 87093227. 3. Seo , A., Sugano, H., Hasegawa, C., Ikeda, K., Nishimura, A., Miyashiro, Y. (Nihon Nohyaku Co., Ltd.). Non-medicinal bactericidal agents and method for their preparation. JP 87093204. 4. Seo, A., Sugano, H., Hasegawa, C., Miyashiro, Y., Nishimura, A., Ikeda, K. (Nihon Nohyaku Co., Ltd.). Ketene S, S-acetals. JP 85218387. 5. Seo, A., Kanno, H., Hasegawa, N. et al. (Nihon Nohyaku Co., Ltd.). A novel ketene S, S-acetal deriv., a process for manufacturing thereof and a method for curing mycosis by administering it. EP 218736.

 

Trade Names

Country Trade name Manufacturer
Japan Astatine Tsumura
Ukraine No No

Formulations

  • 1% cream;
  • 1% ointment;
  • 1% solution

Links

  • EP 218 736 (Nihon Nohyaku; EP-prior. 9.10.1985).
References

1. Oka, H., et al., 1992. Therapeutic efficacy of latoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs. Arzneimittel-Forschung. 42(3): 345-9. PMID: 1497697
2. Niwano, Y., et al., 1994. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs. Antimicrobial agents and chemotherapy. 38(9): 2204-6. PMID: 7811048

http://aac.asm.org/content/38/9/2204.full.pdf

References 1. Seo, A., Kanno, H., Hasegawa, N. et al. (Nihon Nohyaku Co., Ltd.). Antimycotic agent and fungicidal agent. US 4738976. 2. Seo, A ., Sugano, H., Hasegawa, C., Ikeda, K., Munechica, Y., Konoe, T., Konaka, M. (Nihon Nohyaku Co., Ltd.). Antifungal agent. JP 87093227. 3. Seo , A., Sugano, H., Hasegawa, C., Ikeda, K., Nishimura, A., Miyashiro, Y. (Nihon Nohyaku Co., Ltd.). Non-medicinal bactericidal agents and method for their preparation. JP 87093204. 4. Seo, A., Sugano, H., Hasegawa, C., Miyashiro, Y., Nishimura, A., Ikeda, K. (Nihon Nohyaku Co., Ltd.). Ketene S, S-acetals. JP 85218387. 5. Seo, A., Kanno, H., Hasegawa, N. et al. (Nihon Nohyaku Co., Ltd.). A novel ketene S, S-acetal deriv., a process for manufacturing thereof and a method for curing mycosis by administering it. EP 218736.

 

Title: Lanoconazole
CAS Registry Number: 101530-10-3
CAS Name: (E)-(±)-a-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-1H-imidazole-1-acetonitrile
Additional Names: latoconazole
Manufacturers’ Codes: TJN-318; NND-318
Trademarks: Astat (Nihon Nohyaku)
Molecular Formula: C14H10ClN3S2
Molecular Weight: 319.83
Percent Composition: C 52.57%, H 3.15%, Cl 11.08%, N 13.14%, S 20.05%
Literature References: Prepn: A. Soe et al., JP Kokai 85 218387idem et al., US 4636519 (1985, 1987 both to Nihon Nohyaku).In vivo antifungal activity: H. Oka et al., Arzneim.-Forsch. 42, 345 (1992); Y. Niwano et al., Antimicrob. Agents Chemother. 38,2204 (1994). Toxicity study: P. L. Munt et al., Oyo Yakuri 43, 195 (1992).
Properties: Light yellow crystals, mp 141.5°. LD50 in male, female mice, rats (mg/kg): 3224, 2715, 993, 652 orally; 2158, 1743, 1655, 2596 i.p.; >5000 both species s.c. LD50 dermally in rats: >5000 mg/kg (Munt).
Melting point: mp 141.5°
Toxicity data: LD50 in male, female mice, rats (mg/kg): 3224, 2715, 993, 652 orally; 2158, 1743, 1655, 2596 i.p.; >5000 both species s.c.; LD50 dermally in rats: >5000 mg/kg (Munt)
Therap-Cat: Antifungal.
Keywords: Antifungal (Synthetic); Imidazoles.
Share
Sep 292014
 

 

WEBSITE http://www.scientificupdate.co.uk/

SCIENTIFIC UPDATE HAS A REPUTATION FOR ITS HIGH QUALITY EVENTS, BOTH FOR THE SCIENTIFIC CONTENT AND ALSO FOR THE EFFICIENCY OF ITS ORGANISATION. KEEP YOUR SKILLS UP TO DATE AND INVEST IN YOUR CONTINUING PERSONAL PROFESSIONAL DEVELOPMENT.

http://makeinindia.com/

TRAINING COURSE   2-3 DEC 2014

Process Development for Low Cost Manufacturing

When:02.12.2014 – 03.12.2014

Tutors:

Where: National Chemical Laboratory - Pune, India

Brochure:View Brochure

Register http://scientificupdate.co.uk/training/scheduled-training-courses.html

 

DESCRIPTION

Chemical process research and development is recognised as a key function during the commercialisation of a new product particularly in the generic and contract manufacturing arms of the chemical, agrochemical and pharmaceutical industries.

The synthesis and individual processes must be economic, safe and must generate product that meets the necessary quality requirements.

This 2-day course presented by highly experienced process chemists will concentrate on the development and optimisation of efficient processes to target molecules with an emphasis on raw material cost, solvent choice, yield improvement, process efficiency and work up, and waste minimisation.

Process robustness testing and reaction optimisation via stastical methods will also be covered.

A discussion of patent issues and areas where engineering and technology can help reduce operating costs.

The use of engineering and technology solutions to reduce costs will be discussed and throughout the course the emphasis will be on minimising costs and maximising returns.

 

 

Conference 4-5 DEC 2014

TITLE . Organic Process Research & Development – India

Subtitle:The 32nd International Conference and Exhibition

When:04.12.2014 – 05.12.2014

Where:National Chemical Laboratory – Pune, India

Brochure:View Brochure

Register..http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

Organic Process Research & Development - India

for

  • Process Research & Development Chemists
  • Chemical Engineers in Industry
  • Heads of Departments & Team Leaders

Benefits

  • Invest in yourself: keeping up to date on current developments and future trends could mean greater job security.
  • Learn from a wide range of industrial case studies given by hand-picked industrial speakers.
  • Take home relevant ideas and information that are directly applicable to your own work with the full proceedings and a CD of the talks.
  • Save time. Our intensive, commercial-free programme means less time away from work.
  • Meet and network with the key people in the industry in a relaxed and informal atmosphere.

Do you want to improve efficiency and innovation in your synthetic route design, development and optimisation?

The efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance in the chemical and pharmaceutical industries. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently. Indeed, it has never been so important to keep up to date with the latest developments in this dynamic field.

At this Organic Process Research & Development Conference, you will hear detailed presentations and case studies from top international chemists. The hand-picked programme of speakers has been put together specifically for an industrial audience. They will discuss the latest issues relating to synthetic route design, development and optimisation in the pharmaceutical, fine chemical and allied fields.  Unlike other conferences, practically all our speakers are experts from industry, which means the ideas and information you take home will be directly applicable to your own work.

The smaller numbers at our conferences create a more intimate atmosphere. You will enjoy plenty of opportunities to meet and network with speakers and fellow attendees during the reception, sit-down lunches and extended coffee breaks in a relaxed and informal environment. Together, you can explore the different strategies and tactics evolving to meet today’s challenges.

This is held in Pune, close proximity to Mumbai city, very convenient to stay and travel to either in Pune or Mumbai. I feel this should be an opportunity to be grabbed before the conference is full and having no room

Hurry up rush

References

http://newdrugapprovals.org/scientificupdate-uk-on-a-roll/

http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

http://en.wikipedia.org/wiki/Pune

PROFILES

Will Watson

Will Watson

Dr Will Watson gained his PhD in Organic Chemistry from the University of Leeds in 1980. He joined the BP Research Centre at Sunbury-on-Thames and spent five and a half years working as a research chemist on a variety of topics including catalytic dewaxing, residue upgrading, synthesis of novel oxygenates for use as gasoline supplements, surfactants for use as gasoline detergent additives and non-linear optical compounds.

In 1986 he joined Lancaster Synthesis and during the next 7 years he was responsible for laboratory scale production and process research and development to support Lancaster’s catalogue, semi-bulk and custom synthesis businesses.

In 1993 he was appointed to the position of Technical Director, responsible for all Production (Laboratory and Pilot Plant scale), Process Research and Development, Engineering and Quality Control. He helped set up and run the Lancaster Laboratories near Chennai, India and had technical responsibility for the former PCR laboratories at Gainesville, Florida.

He joined Scientific Update as Technical Director in May 2000. He has revised and rewritten the ‘Chemical Development and Scale Up in the Fine Chemical & Pharmaceutical Industries’ course and gives this course regularly around the world. He has been instrumental in setting up and developing new courses such as ‘Interfacing Chemistry with Patents’ and ‘Making and Using Fluoroorganic Molecules’.

He is also involved in an advisory capacity in setting up conferences and in the running of the events. He is active in the consultancy side of the business and sits on the Scientific Advisory Boards of various companies.

………………………………………………………………………………………………….

John Knight

John Knight

Dr John Knight gained a first class honours degree in chemistry at the University of Southampton, UK. John remained at Southampton to study for his PhD in synthetic methodology utilizing radical cyclisation and dipolar cyloaddition chemistry.

After gaining his PhD, John moved to Columbia University, New York, USA where he worked as a NATO Postdoctoral Fellow with Professor Gilbert Stork. John returned to the UK in 1987 joining Glaxo Group Research (now GSK) as a medicinal chemist, where he remained for 4 years before moving to the process research and development department at Glaxo, where he remained for a further 3½ years.

During his time at Glaxo, John worked on a number of projects and gained considerable plant experience (pilot and manufacturing). In 1994 John moved to Oxford Asymmetry (later changing its name to Evotec and most recently to Aptuit) when it had just 25 staff. John’s major role when first at Oxford Asymmetry was to work with a consultant project manager to design, build and commission a small pilot plant, whilst in parallel developing the chemistry PRD effort at Oxford Asymmetry.

The plant was fully operational within 18 months, operating to a 24h/7d shift pattern. John continued to run the pilot plant for a further 3 years, during which time he had considerable input into the design of a second plant, which was completed and commissioned in 2000. After an 18-month period at a small pharmaceutical company, John returned to Oxford in 2000 (by now called Evotec) to head the PRD department. John remained in this position for 6.5 years, during which time he assisted in its expansion, established a team to perform polymorph and salt screening studies and established and maintained high standards of development expertise across the department.

John has managed the chemical development and transfer of numerous NCE’s into the plant for clients and been involved in process validations. He joined Scientific Update in January 2008 as Scientific Director.

Pune images

From top: Fergusson College, Mahatma Gandhi Road (left), Shaniwarwada (right), the HSBC Global Technology India Headquarters, and the National War Memorial Southern Command
From top:1 Fergusson College, 2 Mahatma Gandhi RoadShaniwarwada 3 the HSBC Global Technology India Headquarters, and the 4National War Memorial Southern Command

 

NCL PUNE

The National Chemical Laboratory is located in the state of Maharashtra in India. Maharashtra state is the largest contributor to India’s GDP. The National Chemical Laboratory is located in Pune city, and is the cultural capital of Maharashtra. Pune city is second only to Mumbai (the business capital of India) in size and industrial strength. Pune points of interest include: The tourist places in Pune include: Lal Deval Synagogue, Bund Garden, Osho Ashram, Shindyanchi Chhatri and Pataleshwar Cave Temple.

http://makeinindia.com/

MAKE IN INDIA

http://makeinindia.com/

http://makeinindia.com/sector/pharmaceuticals/

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

 

 

 

KEYWORDS

JOHN KNIGHT, WILL WATSON,  SCIENTIFIC UPDATE, PROCESS, COURSE, CONFERENCE, INDIA, PUNE, PROCESS DEVELOPMENT, LOW COST,  MANUFACTURING, SCALEUP

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: